Chiusura precedente | 11,04 |
Aperto | 11,02 |
Denaro | 0,00 x 0 |
Domanda | 0,00 x 0 |
Min-Max giorno | 10,58 - 11,02 |
Intervallo di 52 settimane | 6,08 - 12,98 |
Volume | |
Media Volume | 11.353 |
Capitalizzazione | 69,527M |
Beta (mensile su 5 anni) | 1,18 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -18,97 |
Prossima data utili | 12 ago 2024 - 16 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 20,33 |
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of pat
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITIL-306 anticipated in 2024 DALLAS, June 26, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the